TrialCurveSocazolimab + chemotherapy in extensive-stage SCLC: reconstructed Kaplan–Meier curves
A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Signal Transduct Target Ther. 2025 Jan 13;10:28. doi: 10.1038/s41392-024-02115-5 |
|---|---|
| DOI | 10.1038/s41392-024-02115-5 |
| Registry | NCT04878016 |
| Phase | Phase 3 |
| Conditions | Extensive-stage Small-cell Lung Cancer |
| Interventions | ZKAB001, Placebo, Carboplatin, Etoposide |
| Sponsor | Lee's Pharmaceutical Limited |
| Enrolment | 498 |
| Source licence | Figure published under CC BY 4.0 |
Overall survival
From figure panel a · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Socazolimab group 13.9 months; Placebo group 11.4 months. Survival at 12 months: Socazolimab group 57%; Placebo group 49%. Hazard ratio Socazolimab group vs Placebo group 0.80 (95% CI 0.65–0.97).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Socazolimab group | 248 | 183 | 13.9 |
| Placebo group | 248 | 202 | 11.4 |
- Socazolimab group vs Placebo group: reconstructed HR 0.80 (95% CI 0.65–0.97)
Landmark survival (reconstructed)
| Time | Socazolimab group | Placebo group |
|---|---|---|
| 6 mo | 89.1% | 85.1% |
| 12 mo | 56.8% | 48.8% |
| 18 mo | 32.1% | 25.7% |
| 24 mo | 20.4% | 5.8% |
Checks against the published figure
- Socazolimab group median: printed 13.9, reconstructed 13.9 pass
- Placebo group median: printed 11.6, reconstructed 11.4 pass
- Socazolimab group events: printed 182, reconstructed 183 pass
- Socazolimab group n: printed 248, reconstructed 248 pass
- Placebo group events: printed 200, reconstructed 202 pass
- Placebo group n: printed 248, reconstructed 248 pass
- hazard ratio (direction inferred): printed 0.799, reconstructed 0.797 pass
Progression-free survival (IRRC, RECIST v1.1)
From figure panel a · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Socazolimab group 5.6 months; Placebo group 4.5 months. Survival at 12 months: Socazolimab group 18%; Placebo group 5%. Hazard ratio Socazolimab group vs Placebo group 0.59 (95% CI 0.47–0.73).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Socazolimab group | 248 | 152 | 5.6 |
| Placebo group | 248 | 185 | 4.5 |
- Socazolimab group vs Placebo group: reconstructed HR 0.59 (95% CI 0.47–0.73)
Landmark survival (reconstructed)
| Time | Socazolimab group | Placebo group |
|---|---|---|
| 6 mo | 42.9% | 22.1% |
| 12 mo | 18.1% | 5.3% |
| 18 mo | 14.9% | 3.2% |
| 24 mo | 14.9% | — |
Checks against the published figure
- Socazolimab group median: printed 5.55, reconstructed 5.58 pass
- Placebo group median: printed 4.37, reconstructed 4.5 pass
- Socazolimab group events: printed 155, reconstructed 152 pass
- Socazolimab group n: printed 248, reconstructed 248 pass
- Placebo group events: printed 185, reconstructed 185 pass
- Placebo group n: printed 248, reconstructed 248 pass
- hazard ratio (direction inferred): printed 0.569, reconstructed 0.588 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- ETER701: Overall survival; Progression-free survival (PFS)
- KEYNOTE-671 (stage II subgroup): Event-free survival; Overall survival
- Rezivertinib in EGFR-mutated NSCLC with CNS metastases: CNS progression-free survival (BICR)
- PRESERVE-003: Overall survival (OS); Progression-free survival (PFS, investigator assessment)
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials